CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 28 enrolled
Drug / intervention
Intranasal capsaicin +1 moredrug
Likely dose
Intranasal capsaicin 2 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05093478
NCT05093478Phase 3Completed

The Prevalence of Local IgE Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population

The University of Texas Health Science Center, Houston·interventional·Posted Oct 26, 2021·Updated Dec 20, 2024

In Brief

A Phase 3 clinical trial evaluating Intranasal capsaicin and topical lidocaine for Non-allergic Rhinitis. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The purpose of this study to determine the therapeutic response of non-allergic rhinitis patients that have been subtyped as non-allergic rhinitis with local IgE elevation or non-allergic rhinopathy to intranasal capsaicin based on visual analog scale and optical rhinometry, to determine the prevalence of non-allergic rhinitis with local IgE elevation in this study's cohort of patients with non-allergic rhinitis identified by rhinitis history and negative skin testing for allergic rhinitis, and to determine the change, if any, in intranasal IgE levels after capsaicin treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedOct 26, 2021
Enrollment StartSep 10, 2019
Primary CompletionNov 30, 2023
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 4.7 years ago

Interventions

Intranasal capsaicindrug

Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.

topical lidocainedrug

The nose will be pre-treated with topical lidocaine 15 minutes before each application